移動体通信装置用誘電体フィルタの工学的研究

取得学位：博士(工学)，学位授与番号：工博甲第2号，学位授与年月日：平成2年3月25

Some Observations on EEG Response to Photic Flicker Stimulation

By applying a combined method of crosscorrelation and frequency analysis to EEG tracings, the average response patterns to photic flicker stimulation with a frequency in the alpha wave range were sorted out, even when the application of the frequency analysis only could not separate the response from the irrelevant oscillations to the stimulation. During the stimulation, low volage fast pattern (alpha blocking state), in which the response was hard to recognize by visual inspection of the tracing, occurred in the EEG tracings from time to time. In the frequency spectra of them, however, not only a peak at the stimulating frequency, but the other ones at slightly higher frequency and sometimes with subharmonic frequency were appeared to suggest they are the response to the stimulation, though they are far lower than the peak of the dominant alpha wave before the initiation of the stimulation, rised up at the stimulating frequency in the power spectra of the crosscorrelogram between the stimulation and the tracing to indicate the other peaks were not related response, at least directly, to the stimulation, but by others

Adult onset cardiac dilatation in a transgenic mouse line with Galβ1,3GalNAc α2,3-sialyltransferase II (ST3Gal-II) transgenes: a new model for dilated cardiomyopathy

Sugar chain abnormalities in glycolipids and glycoproteins are associated with various diseases. Here, we report an adult onset cardiac dilatation in a transgenic mouse line with Galβ1,3GalNAc α2,3-sialyltransferase II (ST3Gal-II) transgenes. The transgenic hearts at the end-stage, at around 7 months old, were enlarged, with enlarged cavities and thin, low-tensile walls, typical of dilated cardiomyopathy. Although no apparent change was found in heart gangliosides, glycosylation of heart proteins was altered. Interestingly, sugar moieties not directly related to the ST3Gal-II catalytic reaction were also changed. Significant increases in calreticulin and calnexin were observed in hearts of the transgenic mice. These results suggest that expression of ST3Gal-II transgenes induces abnormal protein glycosylation, which disorganizes the endoplasmic/sarcoplasmic reticulum quality control system and elevates the calreticulin/calnexin level, resulting in suppression of cardiac function. The transgenic mice showed 100% incidence of adult onset cardiac dilatation, suggesting great potential as a new model for dilated cardiomyopathy

Current state of therapeutic development for rare cancers in Japan, and proposals for improvement

This article discusses current obstacles to the rapid development of safe and effective treatments for rare cancers, and considers measures required to overcome these challenges. In order to develop novel clinical options for rare cancers, which tend to remain left out of novel therapeutic development because of their paucity, efficient recruitment of eligible patients, who tend to be widely dispersed across the country and treated at different centers, is necessary. For this purpose, it is important to establish rare cancer registries that are linked with clinical studies, to organize a central pathological diagnosis system and biobanks for rare cancers, and to consolidate patients with rare cancers to facilities that can conduct clinical studies meeting international standards. Establishing an all‐Japan cooperative network is essential. Clinical studies of rare cancers have considerable limitations in study design and sample size as a result of paucity of eligible patients and, as a result, the level of confirmation of the efficacy and safety shown by the studies is relatively low. Therefore, measures to alleviate these weaknesses inherent to external conditions need to be explored. It is also important to reform the current research environment in order to develop world‐leading treatment for rare cancers, including promotion of basic research, collaboration between industry and academia, and improvement of the infrastructure for clinical studies. Collaboration among a wide range of stakeholders is required to promote the clinical development of treatment for rare cancers under a nationwide consensus

低用量Diethylstilbestrol の妊娠ラットへの投与が雌産子子宮の発達へ及ぼす影響

合成エストロジェンであるジエチルスチルベステロール（DES）を1.5 あるいは0.5 μ g/kg/day（DES 1.5 群あるいはDES 0.5群）の用量で妊娠SD ラットに妊娠7 日目～ 21 日目の期間，連日皮下投与し，産子の子宮の発達に対してどのような影響を及ぼすかについて検討した。胎齢20 日のDES1.5群において，子宮角の長さが増加し，生後3，6 および15 週の長さは短くなった。生後3 および6 週齢のDES1.5 群の子宮角の太さが増加した。さらに生後1 週の子宮内膜上皮細胞の細胞分裂指数も有意に増加した。以上の結果から，胎生期に投与された低濃度のDES は雌産子の子宮の発達に対して促進的な作用を有するが，その作用は恒久的ではないことが示唆された。Diethylstilbestrol (DES), synthetic estrogen, was administered subcutaneously at 0.5 (DES 0.5group) or 1.5 μ g/kg/day (DES 1.5 group) to pregnant Sprague-Dawley (SD) rats daily form days 7 to 21 of gestation to investigate its effects on the development of uteri in female offspring. The lengths of uterine horn in the DES 1.5 group were significantly longer at 20 days of gestation and were significantly shorter at 3, 6 and 15 weeks after birth. The diameters of uterine horns in the DES 1.5 group were significantly larger at 3 and 6 weeks after birth. Furthermore the cell division index of the uterine epithelium in the DES 1.5 group was significantly increased. These observations indicate that prenatal exposure to a low dose of DES a promotes the development of uteri in female SD offspring, but this stimulus effect is not permanent